Smart-Money SignalDistribution · 32/100— Insiders are net sellers over 90 days (-$42.3M, 43 sales vs 21 buys)
Revenue$814.5M
Net Income$197.9M
EPS$1.91
Market Cap$18.2B
Price Performance
Historical data including institutional events
Company Profile
K
Kyle W. Gano
CEO & Executive Director
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
